SCHEMBL5543474

SCHEMBL5543474

C=CCCc1ccc([O])cc1

nearest known ligand 0.37

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
THRB P10828 8/20 0.34
BCHE P06276 2/20 0.33
ACHE P22303 2/20 0.33
THRA P10827 5/20 0.32
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
XDH P47989 1/20 0.30
ALDH1A1 P00352 1/20 0.30
TP53 P04637 1/20 0.30
CYP3A4 P08684 1/20 0.30
ALOX15 P16050 1/20 0.30
TSHR P16473 1/20 0.30
ALOX12 P18054 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
CHKA P35790 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9004469 0.87 GFER (0.36) THRBBCHEACHETHRAMEN1
SCHEMBL5536600 0.86 HDAC1 (0.38) THRBBCHEACHETHRAMEN1
SCHEMBL6285109 0.85 GFER (0.41) THRBBCHEACHETHRAMEN1
SCHEMBL5542872 0.85 USP2 (0.42) THRBTHRAMEN1KMT2AALDH1A1
SCHEMBL8854472 0.80 HRH3 (0.41) THRBXDHALDH1A1TP53CYP3A4
SCHEMBL7789024 0.77 CYP2A6 (0.39) THRBKMT2AALDH1A1SMN1; SMN2
SCHEMBL16682341 0.76 GFER (0.59) MEN1KMT2AALDH1A1CYP3A4TSHR
SCHEMBL9004494 0.76 ALDH1A1 (0.33) THRBXDHALDH1A1
SCHEMBL11477273 0.76 TSHR (0.40) THRBBCHEACHEXDHALDH1A1
SCHEMBL1149698 0.76 TAAR1 (0.50) THRBTHRAALDH1A1TP53TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed
US-5248339-A Polyfluoropolyphazenes EASTMAN KODAK COMPANY (US) 1993-09-28 US disclosed
EP-0454030-A2 Fusing member useful in electrostatography EASTMAN KODAK COMPANY (US) 1991-10-30 EP disclosed
US-4734471-A Method of curing polyfluoroalkoxyphosphazene ETHYL CORPORATION (US) 1988-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 THRB 488/4885BCHE 4833/4885ACHE 4670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.